Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
98P - Trends in and impact of hospital-acquired adverse events in patients with lung cancer undergoing lung resection (ID 341)
12:30 - 13:00 | Author(s): K.C. Mara
Hospital-acquired adverse events are a measure of quality of care delivered and may adversely impact patient outcomes. It is unknown if there been a change in the rates and impact of these adverse events with their increasing recognition as quality measures. We analyzed hospital-acquired adverse events in patients with lung cancer undergoing lung resection using the National Hospital Discharge Survey (NHDS) database from 2001 to 2010.
NHDS collects clinical information on patients dismissed from non-Federal short-stay United States hospitals. Demographics, diagnoses, procedures, and dismissal information were abstracted using ICD-9 diagnosis (162.X) and procedure codes (32.9, 32.3X, 32.4X, and 32.5X). The Agency for Healthcare Research and Quality Patient Safety Indicators (PSIs) were utilized to identify hospital-acquired adverse events. Weighted analyses were performed using SAS version 9.4.
An estimated 585,408 patients with lung cancer underwent lung resection during the study period and were included in the analysis; 58.3% were >65 years, 49.1% women, 66% white. Of these, 153,609 (26.2%) suffered from ≥1-PSI event during their hospitalization. The proportion of patients suffering from ≥1-PSI event consistently increased from 22.0% in 2001–2002, to 34.8% in 2009–2010, p value <0.01. Compared to those with no PSI, patients with ≥1-PSI experienced higher in-hospital mortality (2.2%, vs 15.7%, adjusted odds ratio, 7.8, 95% CI 5.1–11.8), and prolonged length-of-stay (7.8 days, vs 12.5 days, adjusted mean difference, 4.6 days, 95% CI 3.7–5.5), p value for both <0.01.
There was a substantial increase in the frequency of potentially avoidable adverse events in this national database of lung cancer patients undergoing resection, associated with worse outcomes. Although this may in part be due to increasing recognition, interventions are required to prevent these potentially avoidable events.
Clinical trial identification:
Legal entity responsible for the study:
Has not received any funding
All authors have declared no conflicts of interest.